1. Home
  2. NBIX vs RNR Comparison

NBIX vs RNR Comparison

Compare NBIX & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$130.61

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Logo RenaissanceRe Holdings Ltd.

RNR

RenaissanceRe Holdings Ltd.

HOLD

Current Price

$307.76

Market Cap

12.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBIX
RNR
Founded
1992
1993
Country
United States
Bermuda
Employees
N/A
1040
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
12.8B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
NBIX
RNR
Price
$130.61
$307.76
Analyst Decision
Strong Buy
Hold
Analyst Count
22
14
Target Price
$180.82
$314.75
AVG Volume (30 Days)
901.1K
229.6K
Earning Date
05-04-2026
04-28-2026
Dividend Yield
N/A
0.52%
EPS Growth
41.95
N/A
EPS
4.67
N/A
Revenue
$161,626,000.00
N/A
Revenue This Year
$22.85
N/A
Revenue Next Year
$10.36
$2.96
P/E Ratio
$27.09
$5.42
Revenue Growth
977.51
N/A
52 Week Low
$97.30
$222.75
52 Week High
$160.18
$315.88

Technical Indicators

Market Signals
Indicator
NBIX
RNR
Relative Strength Index (RSI) 50.14 60.98
Support Level $124.29 $288.11
Resistance Level $136.23 $312.68
Average True Range (ATR) 4.29 6.78
MACD -0.08 1.18
Stochastic Oscillator 59.64 75.51

Price Performance

Historical Comparison
NBIX
RNR

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About RNR RenaissanceRe Holdings Ltd.

RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.

Share on Social Networks: